top of page
  • Writer's pictureYotam Harnik, PhD

Tracells Emerges as a Pioneer in Gastrointestinal Diagnostics and Therapeutics

We pioneer non-invasive stool tests, leveraging patient transcriptome & an AI-driven classifier, for advanced transcriptomics and precise diagnostics of IBD

REHOVOT, ISRAEL, March 8, 2024 / -- Tracells, an up and coming biotechnology company established by Galil Ofek Innovation accelerator together with Yeda, the commercial arm of the Weizmann Institute of Science, has officially launched with a mission to revolutionize gastrointestinal disease diagnostics and therapeutics, by creating a game-changing non-invasive procedure that would ease the burden on doctors and patients alike.

Tracells is based on cutting-edge research by Prof. Shalev Itzkovitz and his team from the Weizmann Institute of Science, in collaboration with Prof. Bella Ungar from Sheba Medical Center. Leveraging discoveries from two seminal publications in esteemed scientific journals, Tracells is poised to lead the charge in addressing unmet medical needs in the field of non-invasive gastrointestinal diagnostics.


bottom of page